Cogent Biosciences announced positive Phase 3 trial results for its drug bezuclastinib targeting indolent systemic mastocytosis, an immune disorder that causes allergic-like and systemic symptoms. The drug demonstrated statistically significant symptom improvement compared to placebo. Analyst commentary framed the data as highly favorable, establishing Cogent as a competitor to Blueprint Medicines’ Ayvakit. The company is positioning for an FDA submission based on these findings. This progress could impact treatment options for this rare disease and broaden market competition.